Compare Amgen, Inc. (AMGN) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Mercadolibre Inc — how do they compare? Amgen, Inc. trades at $417.92 (market cap $225.15B), while Mercadolibre Inc trades at $1,832 (market cap $92.69B). The key difference: Amgen, Inc. is far larger — about 2.4× Mercadolibre Inc's market cap, and Amgen, Inc. pays a 2.42% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| AMGN | MELI | |
|---|---|---|
Market Cap | $225.15B | $92.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $2.51K |
52-Week Low | $271.18 | $1.55K |
Enterprise Value | $268.47B | $100.34B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.84, up 0.85% today, near its R1 resistance of $418. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, and revenue exceeding $10 billion. Analyst consensus is bullish with 23 Buy ratings, a $392.53 price target, and technical indicators signaling a bullish trend from moving averages, though RSI levels suggest overbought conditions.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high debt levels and competitive pressures. The stock offers a dividend yield supported by consistent payouts, with investor sentiment bolstered by recent earnings outperformance and media coverage highlighting growth prospects.
MercadoLibre (MELI) trades at $1,828.25, down 5.76% over 24 hours amid a bearish technical signal. The company reported strong Q2 2026 results with 50% revenue growth and an EPS beat, though recent quarters show mixed earnings performance. Fundamentals remain robust with $28.89B in 2025 revenue and improving cash flow trends, while valuation metrics like P/E of 49.74 reflect premium pricing. Analyst consensus remains strongly bullish with a $2,150 price target despite margin pressures from growth investments.
The outlook balances exceptional revenue growth against margin compression from strategic investments. Investment opportunity lies in MELI's dominant Latin American e-commerce and fintech ecosystem expansion, while risks include sustained margin pressure, competitive threats, and macroeconomic volatility in key markets. Wall Street's strong buy ratings suggest confidence in long-term growth despite near-term profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
